(S)-(+)-Mecamylamine (TC-5214): A Neuronal Nicotinic Receptor Modulator Enters Phase III Trials as an Adjunct Treatment for Major Depressive Disorder (MDD)
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.